Photo by towfiqu999999 from unsplash
Levodopa/carbidopa intrajejunal gel (LCIG) is an effective therapeutic strategy to overcome levodopa‐induced motor complications in advanced Parkinson's disease (PD). However, it requires invasive percutaneous endoscopic gastrojejunostomy (PEG‐J) and may be… Click to show full abstract
Levodopa/carbidopa intrajejunal gel (LCIG) is an effective therapeutic strategy to overcome levodopa‐induced motor complications in advanced Parkinson's disease (PD). However, it requires invasive percutaneous endoscopic gastrojejunostomy (PEG‐J) and may be associated with serious adverse effects (AE). In this study, we aimed to evaluate long‐term AEs related to LCIG treatment in a large homogenous cohort of advanced PD patients.
Keywords:
long term;
intrajejunal gel;
levodopa carbidopa;
adverse effects;
carbidopa intrajejunal
Journal Title: Acta Neurologica Scandinavica
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Acta Neurologica Scandinavica
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!